Immunicum AB (publ) Interim Report January – March 2020

NEXT STORY
Orion Group Interim Report 1-3/2020
PREV STORY
New 6-year data for Roche’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Basilea announces positive results of phase 3 TARGET study with antibiotic ceftobiprole in the treatment of acute bacterial skin and skin structure infections (ABSSSI)

author_avatar
NASDAQ Market News

Calithera Biosciences Initiates Phase 1b Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis

author_avatar
NASDAQ Market News

Covid-19 Data Published in the American Journal of Respiratory and Critical Care Medicine: NovaSignal’s Lucid™ Robotic System Used by Mount Sinai Health System Uncovers Possible Breakthrough in Patients with Covid-19

author_avatar
NASDAQ Market News